News from ODYSSEY OUTCOMES: Effects of PCSK9 inhibition on total cardiovascular disease burden New US Cholesterol Guidelines: The good, the bad and the ugly News from FOURIER: Benefit with evolocumab across all vascular territories Will evinacumab eliminate the need for LDL-apheresis in patients with homozygous FH?More insights from ORION Long-term evinacumab in homozygous FH ODYSSEY OUTCOMES Economics Study: How can we get the best value from PCSK9 inhibitors?Alirocumab safe in patients with diabetes mellitus

Jan Boren Articles

Hepatic lipid metabolism: Storage vs secretion

Reports from the 10th Closed Expert Meeting of the PCSK9 Education and Research Forum Jan Boren

Posted on 8 August 2019 | Posted by Jan Boren | Posted in Webcasts, 10th Closed Scientific Expert Meeting of the Editorial Board

ApoB-containing lipoproteins and the pathophysiology of atherosclerotic vascular disease: update

Jan Boren

Posted on 12 January 2016 | Posted by Jan Boren | Posted in Webcasts, 3rd Closed Scientific Expert Meeting of the Editorial Board

About PCSK9 Education and Research Forum

PCSK9 Education and Research Forum is a not-for-profit organisation established by leading researchers in the fields of atherosclerosis, lipids and cardiovascular disease. Our mission is to raise awareness and knowledge of the significant role played by PCSK9 in lipid metabolism and its value as a novel therapeutic target.

Editorial Policy

Unless otherwise indicated, opinions expressed in the PCSK9 Education and Research Forum are those of the contributors. All patients should discuss their medication with their healthcare professional. Although every effort is made to ensure accuracy and avoid mistakes, no liability on the part of the PCSK9 Forum, the editors or the editorial board is accepted for the consequences of any misleading or inaccurate information.

Educational Partners and Supporters